Form 4: Emergent BioSolutions EVP's PSU Vesting at 25% Target

Emergent BioSolutions EVP Coleen Glessner's performance stock units, tied to cumulative revenue and adjusted EBITDA, vested at only 25% of their target for the 2023-2025 period.

Summary

• Coleen Glessner, EVP, Quality & Ethics, and CPL at Emergent BioSolutions Inc. (EBS), reported transactions related to her beneficial ownership.
• On February 6, 2026, performance stock units (PSUs) granted under the company's Stock Incentive Plan vested.
• The PSUs were tied to the achievement of cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue over the three-year period from January 1, 2023, to December 31, 2025.
• The Compensation Committee certified the achievement at a payout factor of 25% of target.
• This resulted in an actual award of 9,615 shares of common stock, significantly less than the 38,462 shares previously reported as target on March 2, 2023, and June 9, 2023.
• A disposition of 28,847 shares of common stock was reported at a price of $10.92 per share, reflecting the settlement of the PSUs.
• Additionally, 2,852 shares of common stock were withheld at $10.92 per share to cover taxes associated with the vesting and settlement of restricted stock units.
• Following these transactions, Coleen Glessner beneficially owns 112,620 shares of common stock directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal, primarily due to the significant underperformance against executive compensation targets tied to critical financial metrics, which suggests underlying business challenges.

Positives

• The executive received an award of 9,615 shares of common stock, indicating that some level of performance criteria was met, albeit at a reduced rate.

Negatives

• The performance stock units vested at only 25% of their target, signifying substantial underperformance against the established financial goals for cumulative revenues and adjusted EBITDA over the 2023-2025 period.

Risks

• Underperformance against key financial targets, specifically cumulative revenues and adjusted EBITDA, as evidenced by the 25% PSU payout factor.

Future Outlook

N/A. This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance.

Management Comments

• The Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target.

Industry Context

StockSavvy.ai notes that a low performance stock unit payout, particularly one tied to key financial metrics like revenue and EBITDA, can signal company-specific operational challenges or broader headwinds within the biotechnology sector, potentially impacting investor confidence. This outcome suggests Emergent BioSolutions may have faced difficulties in meeting its internal financial objectives during the 2023-2025 period.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the low PSU payout as a negative indicator of the company's financial performance and management's ability to meet strategic goals, potentially impacting investor confidence and stock valuation.
• Employees: Could perceive the underperformance against targets as a reflection of broader company challenges, potentially affecting morale or future incentive programs.

Next Steps

• N/A. The filing does not mention any specific future actions, events, or milestones.

Key Dates

Recommendation

The vesting of performance stock units at only 25% of target, based on critical financial metrics like cumulative revenues and adjusted EBITDA, signals significant underperformance by Emergent BioSolutions against its internal goals for the 2023-2025 period. This indicates potential underlying operational or market challenges that could negatively impact future financial results and shareholder value, warranting a 'sell' recommendation for seasoned investors.

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Performance Stock Units, PSU, Executive Compensation, Stock Incentive Plan, Revenue, EBITDA, Stock Vesting, Corporate Governance